222 related articles for article (PubMed ID: 36834764)
1. Implementation of Novel Affinity Ligand for Lentiviral Vector Purification.
Moreira AS; Bezemer S; Faria TQ; Detmers F; Hermans P; Sierkstra L; Coroadinha AS; Peixoto C
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834764
[TBL] [Abstract][Full Text] [Related]
2. Clinical grade lentiviral vector purification and quality control requirements.
Shi R; Jia S; Liu H; Nie H
J Sep Sci; 2022 Jun; 45(12):2093-2101. PubMed ID: 35247228
[TBL] [Abstract][Full Text] [Related]
3. Peptide ligands targeting the vesicular stomatitis virus G (VSV-G) protein for the affinity purification of lentivirus particles.
Barbieri E; Mollica GN; Moore BD; Sripada SA; Shastry S; Kilgore RE; Loudermilk CM; Whitacre ZH; Kilgour KM; Wuestenhagen E; Aldinger A; Graalfs H; Rammo O; Schulte MM; Johnson TF; Daniele MA; Menegatti S
Biotechnol Bioeng; 2024 Feb; 121(2):618-639. PubMed ID: 37947118
[TBL] [Abstract][Full Text] [Related]
4. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification.
Segura MM; Garnier A; Durocher Y; Coelho H; Kamen A
Biotechnol Bioeng; 2007 Nov; 98(4):789-99. PubMed ID: 17461423
[TBL] [Abstract][Full Text] [Related]
5. Optimized Lentiviral Transduction Protocols by Use of a Poloxamer Enhancer, Spinoculation, and scFv-Antibody Fusions to VSV-G.
Anastasov N; Höfig I; Mall S; Krackhardt AM; Thirion C
Methods Mol Biol; 2016; 1448():49-61. PubMed ID: 27317172
[TBL] [Abstract][Full Text] [Related]
6. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application.
Merten OW; Charrier S; Laroudie N; Fauchille S; Dugué C; Jenny C; Audit M; Zanta-Boussif MA; Chautard H; Radrizzani M; Vallanti G; Naldini L; Noguiez-Hellin P; Galy A
Hum Gene Ther; 2011 Mar; 22(3):343-56. PubMed ID: 21043787
[TBL] [Abstract][Full Text] [Related]
7. Optimized Pre-Clinical Grade Production of Two Novel Lentiviral Vector Pseudotypes for Lung Gene Delivery.
Rosales Gerpe MC; van Lieshout LP; Domm JM; van Vloten JP; Datu J; Ingrao JC; Yu DL; de Jong J; Moraes TJ; Krell PJ; Bridle BW; Wootton SK
Hum Gene Ther; 2020 Apr; 31(7-8):459-471. PubMed ID: 32000531
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral Vector Purification Using Genetically Encoded Biotin Mimic in Packaging Cell.
Mekkaoui L; Parekh F; Kotsopoulou E; Darling D; Dickson G; Cheung GW; Chan L; MacLellan-Gibson K; Mattiuzzo G; Farzaneh F; Takeuchi Y; Pule M
Mol Ther Methods Clin Dev; 2018 Dec; 11():155-165. PubMed ID: 30547049
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in lentiviral vector development and applications.
Mátrai J; Chuah MK; VandenDriessche T
Mol Ther; 2010 Mar; 18(3):477-90. PubMed ID: 20087315
[TBL] [Abstract][Full Text] [Related]
10. The stability of envelope-pseudotyped lentiviral vectors.
Dautzenberg IJC; Rabelink MJWE; Hoeben RC
Gene Ther; 2021 Feb; 28(1-2):89-104. PubMed ID: 32973351
[TBL] [Abstract][Full Text] [Related]
11. Development of Large-Scale Downstream Processing for Lentiviral Vectors.
Valkama AJ; Oruetxebarria I; Lipponen EM; Leinonen HM; Käyhty P; Hynynen H; Turkki V; Malinen J; Miinalainen T; Heikura T; Parker NR; Ylä-Herttuala S; Lesch HP
Mol Ther Methods Clin Dev; 2020 Jun; 17():717-730. PubMed ID: 32346549
[TBL] [Abstract][Full Text] [Related]
12. Characterization and comparative performance of lentiviral vector preparations concentrated by either one-step ultrafiltration or ultracentrifugation.
Papanikolaou E; Kontostathi G; Drakopoulou E; Georgomanoli M; Stamateris E; Vougas K; Vlahou A; Maloy A; Ware M; Anagnou NP
Virus Res; 2013 Jul; 175(1):1-11. PubMed ID: 23583684
[TBL] [Abstract][Full Text] [Related]
13. Generation of High-Titer Pseudotyped Lentiviral Vectors.
Hu S; Li M; Akkina R
Methods Mol Biol; 2019; 1937():125-134. PubMed ID: 30706393
[TBL] [Abstract][Full Text] [Related]
14. Downstream processing of lentiviral vectors: releasing bottlenecks.
Bandeira V; Peixoto C; Rodrigues AF; Cruz PE; Alves PM; Coroadinha AS; Carrondo MJ
Hum Gene Ther Methods; 2012 Aug; 23(4):255-63. PubMed ID: 22934827
[TBL] [Abstract][Full Text] [Related]
15. Pseudotyped Lentiviral Vectors: One Vector, Many Guises.
Joglekar AV; Sandoval S
Hum Gene Ther Methods; 2017 Dec; 28(6):291-301. PubMed ID: 28870117
[TBL] [Abstract][Full Text] [Related]
16. Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications.
Transfiguracion J; Jaalouk DE; Ghani K; Galipeau J; Kamen A
Hum Gene Ther; 2003 Aug; 14(12):1139-53. PubMed ID: 12908966
[TBL] [Abstract][Full Text] [Related]
17. Toward a Scalable Purification Protocol of GaLV-TR-Pseudotyped Lentiviral Vectors.
Boudeffa D; Bertin B; Biek A; Mormin M; Leseigneur F; Galy A; Merten OW
Hum Gene Ther Methods; 2019 Oct; 30(5):153-171. PubMed ID: 31516018
[TBL] [Abstract][Full Text] [Related]
18. Cancer Gene Therapy: Development and Production of Lentiviral Vectors for Gene Therapy.
Coroadinha AS
Methods Mol Biol; 2022; 2521():297-315. PubMed ID: 35733005
[TBL] [Abstract][Full Text] [Related]
19. Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.
Mendenhall A; Lesnik J; Mukherjee C; Antes T; Sengupta R
J Vis Exp; 2012 Apr; (62):e3171. PubMed ID: 22508377
[TBL] [Abstract][Full Text] [Related]
20. Production of lentiviral vectors for transducing cells from the central nervous system.
Li M; Husic N; Lin Y; Snider BJ
J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
